CCTG has opened the anticipated international brain cancer study CCTG CE9 (LUMOS2) - joining forces with the Australian Cooperative Trials Group for Neuro-Oncology (COGNO) to make enrollment accessible to Canadian patients.
Botensilimab + Balstilimab vs Best Supportive Care as Therapy in Chemo-refractory, Unresectable, Colorectal Adenocarcinoma: The BATTMAN Trial
STRIDE (durvalumab + tremelimumab) with Lenvatinib vs STRIDE Alone in Patients with Unresectable Hepatocellular Carcinoma (SLIDE-HCC)
The CCTG ES3 NEEDS international esophageal cancer clinical trial is now opened in Canada. The study is investigating whether delaying surgery for patients with squamous cell carcinoma of the esophagus is as good as the current treatment.
Venetoclax and HMA-based Therapies for the Treatment of Older and Unfit Adults with Newly Diagnosed FLT3-mutated AML: A myeloMATCH Treatment Trial
Phase 2 Trial of ASTX727 and Venetoclax Compared with ASTX727, Venetoclax, and Enasidenib for Newly Diagnosed Older Adults with IDH2 Mutant AML - A myeloMATCH Substudy
Eradicating MRD in Patients with AML prior to Stem Cell Transplant (ERASE)
LUNA-2: LND101 in Unresectable Non-Small Cell Lung Cancer: A Randomized Phase II Trial
VIGOR: Vorasidenib as Maintenance Treatment after First-line Chemoradiotherapy in IDH-mutant Grade 2 or 3 Astrocytoma
RAINBO-ORANGE: Treatment of Endometrial Cancer Based On Molecular Features
CCTG IND232 (NCT02788773) - A Phase II Study of Durvalumab with or without Tremelimumab in Patients with Metastatic Castration Resistant Prostate Cancer has been closed to accrual after the completion of target accrual.
The use of Complementary Medicines is Relatively High Among Patients in Phase III Cancer Trials
Dr. McKenzie is a radiation oncologist with extensive experience in genitourinary oncology, neurooncology and palliative oncology. He currently works as a radiation oncologist at BC Cancer Vancouver. He also is the co-chair of the CCTG Supportive Care Committee. In this video, McKenzie addresses the wide variety of trials the Supportive Care Committee is involved with, as well as potential avenues for new trials that may extend beyond the jurisdiction of cancer research.
This past weekend at the European Society for Medical Oncology congress in Barcelona, Spain, there were many poster presentations by CCTG researchers.
Poster Discussion: CCTG IND 232 - Phase II Study of Durvalumab with or without Tremelimumab in Patients with mCRPC
An emerging form of immunotherapy, called adoptive cell transfer, has the potential to transform the way in which cancers are treated. Adoptive cell therapy involves taking a patient’s immune cells from their blood, and modifying them in a lab so they can target cancer cells more effectively — enhancing the patient’s immune system to fight cancer.
CCTG SC.24, A Randomized Phase II/III Study Comparing Stereotactic Body Radiotherapy (SBRT) versus Conventional Palliative Radiotherapy (CRT) for Patients with Spinal Metastases, has been closed to accrual after the completion of target accrual. Although the trial is closed accrual, treatment and follow up of patients will continue according to the protocol.
The purpose of this study is to find out if SBRT is better than CRT at controlling pain in the spine 3 months after receiving treatment.
The CCTG IND.225 trial: A Phase II Study of the Assessment of Response to Pembrolizumab in Metastatic Melanoma: CT Texture Analysis as a Predictive Biomarker has been permanently closed/terminated.
The CCTG Central Operations and Statistics Office located at Queen's University in Kingston, Ontario has a job opening for a two Study Coordinators and a Research Associate.
